刚刚!总局宣布修订跌打万花油等32种非处方药说明书

2018-01-10 佚名 CFDA

刚刚,国家食品药品监督管理总局发布了一则公告,将修订跌打万花油等多打32种非处方药的说明书。

刚刚,国家食品药品监督管理总局发布了一则公告,将修订跌打万花油等多达32种非处方药的说明书。

公告原文如下:

根据监测评价结果,为进一步保障公众用药安全,国家食品药品监督管理总局决定对跌打万花油等32种非处方药说明书进行修订。现将有关事项公告如下:

一、各相关非处方药生产企业均应依据《药品注册管理办法》等有关规定,按照跌打万花油等32种非处方药说明书范本(见附件),提出修订说明书的补充申请,于2018年1月31日前报省级食品药品监管部门备案。

修订内容涉及药品标签的,应当一并进行修订;说明书及标签其他内容应当与原批准内容一致。在补充申请备案之日起生产的药品,不得继续使用原药品说明书。

各相关非处方药生产企业应当采取有效措施做好跌打万花油等32种药品使用和安全性问题的宣传和培训,指导医师和患者合理用药。

二、临床医师应当仔细阅读跌打万花油等32种药品说明书的修订内容,在选择用药时,应当根据新修订说明书进行充分的效益∕风险分析。

三、跌打万花油等32种药品为非处方药,患者用药前应当仔细阅读跌打万花油等32种药品说明书的新修订内容。

特此公告。

食品药品监管总局

2017年12月28日

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1819204, encodeId=096c1819204e4, content=<a href='/topic/show?id=0805993615a' target=_blank style='color:#2F92EE;'>#非处方#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99361, encryptionId=0805993615a, topicName=非处方)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f98e185, createdName=psybestwish, createdTime=Thu Nov 15 13:08:00 CST 2018, time=2018-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507166, encodeId=a2c2150e16603, content=<a href='/topic/show?id=18849189139' target=_blank style='color:#2F92EE;'>#说明书#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91891, encryptionId=18849189139, topicName=说明书)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3da79876963, createdName=yangpeizhi, createdTime=Fri Jan 12 01:08:00 CST 2018, time=2018-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589650, encodeId=aa471589650f8, content=<a href='/topic/show?id=10f299362a1' target=_blank style='color:#2F92EE;'>#非处方药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99362, encryptionId=10f299362a1, topicName=非处方药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=716117772264, createdName=gracezdd, createdTime=Fri Jan 12 01:08:00 CST 2018, time=2018-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=277185, encodeId=2ea82e7185c2, content=henhao, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NcXNhUvfhzd2VdicMnaLeK2Im5gKx4Ucxd8Bwu6S7RG0uILBFQx5HTW2bU4VricDYlQqN20ibASSMYAeGrZrrTpy2Q/0, createdBy=7dcf1938111, createdName=1e0e5a1fm42(暂无匿称), createdTime=Wed Jan 10 12:18:30 CST 2018, time=2018-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=277149, encodeId=90812e7149aa, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Wed Jan 10 10:53:34 CST 2018, time=2018-01-10, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1819204, encodeId=096c1819204e4, content=<a href='/topic/show?id=0805993615a' target=_blank style='color:#2F92EE;'>#非处方#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99361, encryptionId=0805993615a, topicName=非处方)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f98e185, createdName=psybestwish, createdTime=Thu Nov 15 13:08:00 CST 2018, time=2018-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507166, encodeId=a2c2150e16603, content=<a href='/topic/show?id=18849189139' target=_blank style='color:#2F92EE;'>#说明书#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91891, encryptionId=18849189139, topicName=说明书)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3da79876963, createdName=yangpeizhi, createdTime=Fri Jan 12 01:08:00 CST 2018, time=2018-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589650, encodeId=aa471589650f8, content=<a href='/topic/show?id=10f299362a1' target=_blank style='color:#2F92EE;'>#非处方药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99362, encryptionId=10f299362a1, topicName=非处方药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=716117772264, createdName=gracezdd, createdTime=Fri Jan 12 01:08:00 CST 2018, time=2018-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=277185, encodeId=2ea82e7185c2, content=henhao, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NcXNhUvfhzd2VdicMnaLeK2Im5gKx4Ucxd8Bwu6S7RG0uILBFQx5HTW2bU4VricDYlQqN20ibASSMYAeGrZrrTpy2Q/0, createdBy=7dcf1938111, createdName=1e0e5a1fm42(暂无匿称), createdTime=Wed Jan 10 12:18:30 CST 2018, time=2018-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=277149, encodeId=90812e7149aa, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Wed Jan 10 10:53:34 CST 2018, time=2018-01-10, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1819204, encodeId=096c1819204e4, content=<a href='/topic/show?id=0805993615a' target=_blank style='color:#2F92EE;'>#非处方#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99361, encryptionId=0805993615a, topicName=非处方)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f98e185, createdName=psybestwish, createdTime=Thu Nov 15 13:08:00 CST 2018, time=2018-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507166, encodeId=a2c2150e16603, content=<a href='/topic/show?id=18849189139' target=_blank style='color:#2F92EE;'>#说明书#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91891, encryptionId=18849189139, topicName=说明书)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3da79876963, createdName=yangpeizhi, createdTime=Fri Jan 12 01:08:00 CST 2018, time=2018-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589650, encodeId=aa471589650f8, content=<a href='/topic/show?id=10f299362a1' target=_blank style='color:#2F92EE;'>#非处方药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99362, encryptionId=10f299362a1, topicName=非处方药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=716117772264, createdName=gracezdd, createdTime=Fri Jan 12 01:08:00 CST 2018, time=2018-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=277185, encodeId=2ea82e7185c2, content=henhao, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NcXNhUvfhzd2VdicMnaLeK2Im5gKx4Ucxd8Bwu6S7RG0uILBFQx5HTW2bU4VricDYlQqN20ibASSMYAeGrZrrTpy2Q/0, createdBy=7dcf1938111, createdName=1e0e5a1fm42(暂无匿称), createdTime=Wed Jan 10 12:18:30 CST 2018, time=2018-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=277149, encodeId=90812e7149aa, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Wed Jan 10 10:53:34 CST 2018, time=2018-01-10, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1819204, encodeId=096c1819204e4, content=<a href='/topic/show?id=0805993615a' target=_blank style='color:#2F92EE;'>#非处方#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99361, encryptionId=0805993615a, topicName=非处方)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f98e185, createdName=psybestwish, createdTime=Thu Nov 15 13:08:00 CST 2018, time=2018-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507166, encodeId=a2c2150e16603, content=<a href='/topic/show?id=18849189139' target=_blank style='color:#2F92EE;'>#说明书#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91891, encryptionId=18849189139, topicName=说明书)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3da79876963, createdName=yangpeizhi, createdTime=Fri Jan 12 01:08:00 CST 2018, time=2018-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589650, encodeId=aa471589650f8, content=<a href='/topic/show?id=10f299362a1' target=_blank style='color:#2F92EE;'>#非处方药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99362, encryptionId=10f299362a1, topicName=非处方药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=716117772264, createdName=gracezdd, createdTime=Fri Jan 12 01:08:00 CST 2018, time=2018-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=277185, encodeId=2ea82e7185c2, content=henhao, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NcXNhUvfhzd2VdicMnaLeK2Im5gKx4Ucxd8Bwu6S7RG0uILBFQx5HTW2bU4VricDYlQqN20ibASSMYAeGrZrrTpy2Q/0, createdBy=7dcf1938111, createdName=1e0e5a1fm42(暂无匿称), createdTime=Wed Jan 10 12:18:30 CST 2018, time=2018-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=277149, encodeId=90812e7149aa, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Wed Jan 10 10:53:34 CST 2018, time=2018-01-10, status=1, ipAttribution=)]
    2018-01-10 1e0e5a1fm42(暂无匿称)

    henhao

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1819204, encodeId=096c1819204e4, content=<a href='/topic/show?id=0805993615a' target=_blank style='color:#2F92EE;'>#非处方#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99361, encryptionId=0805993615a, topicName=非处方)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f98e185, createdName=psybestwish, createdTime=Thu Nov 15 13:08:00 CST 2018, time=2018-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507166, encodeId=a2c2150e16603, content=<a href='/topic/show?id=18849189139' target=_blank style='color:#2F92EE;'>#说明书#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91891, encryptionId=18849189139, topicName=说明书)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3da79876963, createdName=yangpeizhi, createdTime=Fri Jan 12 01:08:00 CST 2018, time=2018-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589650, encodeId=aa471589650f8, content=<a href='/topic/show?id=10f299362a1' target=_blank style='color:#2F92EE;'>#非处方药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99362, encryptionId=10f299362a1, topicName=非处方药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=716117772264, createdName=gracezdd, createdTime=Fri Jan 12 01:08:00 CST 2018, time=2018-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=277185, encodeId=2ea82e7185c2, content=henhao, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NcXNhUvfhzd2VdicMnaLeK2Im5gKx4Ucxd8Bwu6S7RG0uILBFQx5HTW2bU4VricDYlQqN20ibASSMYAeGrZrrTpy2Q/0, createdBy=7dcf1938111, createdName=1e0e5a1fm42(暂无匿称), createdTime=Wed Jan 10 12:18:30 CST 2018, time=2018-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=277149, encodeId=90812e7149aa, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Wed Jan 10 10:53:34 CST 2018, time=2018-01-10, status=1, ipAttribution=)]
    2018-01-10 Y—xianghai

    学习了新知识

    0

相关资讯

药监局将36种药品转换为非处方药品

  根据经国家食品药品监督管理局网站近日消息,国家食品药品监督管理局将安尔眠胶囊等36种药品(化学药品9种,中成药27种)转换为非处方药,并发布了转换的36种药品名单(下表)及其非处方药说明书范本(附件)。国家食品药品监督管理局还要求相关部门进行以上品种说明书和标签的变更工作。   下载附件:安尔眠胶囊等36种非处方药说明书范本 转换为非处方药的36种药品名单 

肠炎宁颗粒等14种药品转换为非处方药

国家食品药品监督管理总局办公厅日前发布通知:根据《处方药与非处方药分类管理办法(试行)》(国家药品监督管理局令第10号)的规定,经总局组织论证和审定,肠炎宁颗粒等14种药品(化学药品1种,中成药13种)转换为非处方药。   序号 药品名称

Int J Clin Pharm:孕期过分谨慎用药反而对有害于胎儿的健康

近日,来自东安格利亚大学药学院的一项新的研究发现,孕妇对处方和非处方药的使用过于谨慎。研究共纳入了1120名女性,对于妊娠常见症状如恶心、泌尿道感染和疼痛,很多参与者并不愿意接受治疗。通过在线调查收集参与者孕期所发生的常见症状的数据。询问参与者药物治疗这些症状有害还是有益以及是否有意避免孕期使用药物,如果是继续询问是哪些药物。结果发现,约四分之三的参与者(76.4 %)的妇女服用过处方或非处方药。